Trial Profile
A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Mar 2014 New trial record
- 13 Nov 2013 The status of trial has changed to completed from recruiting as reported by ClinicalTrials.gov record.